Emerging therapeutic drugs for AML Journal Article
| Authors: | Stein, E. M.; Tallman, M. S. |
| Article Title: | Emerging therapeutic drugs for AML |
| Abstract: | Multiple new drugs are being developed to treat acute myeloid leukemia (AML), including novel formulations of traditional chemotherapy-antibody drug conjugates and agents that target specific mutant enzymes. Next-generation sequencing has allowed us to discover the genetic mutations that lead to the development and clinical progression of AML. Studies of clonal hierarchy suggest which mutations occur early and dominate. This has led to targeted therapy against mutant driver proteins as well as the development of drugs such as CPX-351 and SGN-CD33A whose mechanisms of action and efficacy may not be dependent on mutational complexity. In this brief review, wediscuss drugs that may emerge as important for the treatment of AML in the next 10 years. © 2016 by The American Society of Hematology. |
| Keywords: | cancer chemotherapy; unclassified drug; histone deacetylase inhibitor; review; antineoplastic agent; protein kinase inhibitor; acute myeloblastic leukemia; drug formulation; randomized controlled trial (topic); molecularly targeted therapy; phase 2 clinical trial (topic); phase 3 clinical trial (topic); phase 1 clinical trial (topic); midostaurin; decitabine; quizartinib; vosaroxin; human; priority journal; oxidoreductase inhibitor; bromodomain inhibitor; volasertib; pinometostat; venetoclax; crenolanib; cytarabine plus daunorubicin; drug antibody; fms related tyrosine kinase 3 inhibitor; gilteritinib; guadecitabine; isocitrate dehydrogenase 1 inhibitor; isocitrate dehydrogenase 2 inhibitor |
| Journal Title: | Blood |
| Volume: | 127 |
| Issue: | 1 |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2016-01-07 |
| Start Page: | 71 |
| End Page: | 78 |
| Language: | English |
| DOI: | 10.1182/blood-2015-07-604538 |
| PROVIDER: | scopus |
| PUBMED: | 26660428 |
| PMCID: | PMC4915807 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 3 March 2016 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work